Company news
Veru Inc. (NASDAQ:VERU) news
Veru Inc. news releases on 6ix. Latest, Mar 12, 2024: Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program…
Press releases — page 2
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
March 11, 2024
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
February 26, 2024
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
February 19, 2024
Veru Reports Fiscal 2024 First Quarter Financial Highlights
February 7, 2024
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
February 5, 2024
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
January 24, 2024
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
January 7, 2024
Veru Announces Pricing of Public Offering of Common Stock
December 13, 2023
Veru Announces Proposed Public Offering of Common Stock
December 12, 2023
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Incr...
October 3, 2023
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
September 25, 2023
Veru Reports Fiscal 2023 Third Quarter Financial Results
August 9, 2023
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
August 2, 2023
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
May 31, 2023
Veru Reports Fiscal 2023 Second Quarter Financial Results
May 10, 2023
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
May 3, 2023
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
May 2, 2023
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
April 26, 2023
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
April 19, 2023
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
April 18, 2023
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
April 10, 2023
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
April 3, 2023
Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
March 1, 2023
Veru Reports Fiscal 2023 First Quarter Financial Results
February 8, 2023
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
January 25, 2023
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
January 9, 2023
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
December 4, 2022
Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
November 27, 2022
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
November 8, 2022
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
October 23, 2022
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 3, 2022
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
September 18, 2022
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
September 6, 2022
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
August 21, 2022
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
August 18, 2022
Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories
August 10, 2022
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August...
August 8, 2022
Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th
July 27, 2022
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
July 5, 2022
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
June 6, 2022
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
June 5, 2022
Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients
May 17, 2022
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
May 11, 2022
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
May 1, 2022
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infe...
April 24, 2022
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
April 10, 2022
Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference
March 3, 2022
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
February 16, 2022
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
February 13, 2022
Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
February 8, 2022